You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 10, October 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Growth Hormone Therapy in Hypophosphatemic Rickets

Darrell M. Wilson, MD; Phillip D. K. Lee, MD; Alan H. Morris, MD; Edward O. Reiter, MD; Joseph M. Gertner, MB, MRCP; Robert Marcus, MD; Valerie E. Quarmby, PhD; Ron G. Rosenfeld, MD

Am J Dis Child. 1991;145(10):1165-1170.


Abstract

• The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93±0.13 mmol/L (mean±SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70±0.08 mmol/L to 0.83±0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.

(AJDC. 1991;145:1165-1170)



Author Affiliations

From the Departments of Pediatrics, Stanford (Calif) University (Drs Wilson and Rosenfeld); University of Colorado Health Science Center, Denver (Dr Lee); The City of Hope Hospital, Duarte, Calif (Dr Morris); Baystate Medical Center, Tufts University of School of Medicine, Springfield, Mass (Dr Reiter); Cornell University Medical College, New York, NY (Dr Gertner); the Department of Medicine, Stanford University (Dr Marcus); and Peptide Section, Endocrine Sciences, Calabasas Hills, Calif (Dr Quarmby). Dr Lee is now with the Department of Pediatrics, Baylor College of Medicine, Houston, Tex.


Footnotes

Accepted for publication May 20, 1991.

Read in part before the Eighth Congress of the International Pediatric Nephrology Association, Toronto, Ontario, August 31, 1989, the Society of Pediatric Research, Anaheim, Calif, May 10, 1990, and the Third Eli Lilly International Symposium on Endocrine Disorders, Stanford, Calif, May 9, 1990.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets
Haffner et al.
Pediatrics 2004;113:e593-e596.
ABSTRACT | FULL TEXT  

Acid-base Homeostasis in Children With Growth Hormone Deficiency
Glaser et al.
Pediatrics 1998;102:1407-1414.
ABSTRACT | FULL TEXT  

The Effect of Recombinant Human Growth Hormone in Children With X-Linked Hypophosphatemia
Seikaly et al.
Pediatrics 1997;100:879-884.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.